DelveInsight publishes 2026 Psoriatic Arthritis pipeline analysis
DelveInsight's new report offers a comprehensive overview of the psoriatic arthritis pipeline and emerging therapies expected by 2026, analyzing over 20 companies and 25 drug candidates.
Research firm DelveInsight has released its "Psoriatic Arthritis– Pipeline Insight, 2026" report, providing a global overview of the therapeutic landscape. The analysis covers more than 20 companies and over 25 drug candidates in development for psoriatic arthritis (PsA).
Psoriatic arthritis is a chronic inflammatory condition linked to psoriasis, affecting approximately 20% of individuals with the skin disease. Symptoms can include joint pain, swelling, and stiffness, alongside skin manifestations.
The report details pipeline drug profiles, categorizing them by clinical and non-clinical stages. It also assesses therapies based on product type, development stage, route of administration, and molecule type, while identifying inactive pipeline products.
DelveInsight's analysis highlights current treatment strategies for PsA, which focus on controlling inflammation, preventing joint damage, and managing skin symptoms. The pharmaceutical industry is developing a range of treatments, including conventional and targeted disease-modifying antirheumatic drugs (DMARDs), as well as newer oral medications.